

Forschungsprojekte 2021

Projets de recherche 2021

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Grundlagenforschung / Recherche fondamentale			
<u>Gesuchsteller/In</u>	<u>Projektnummer</u> <u>Projekttitle</u>	<u>Dauer</u> (Monate)	<u>Betrag</u> (CHF)
<u>Candidat/e</u>	<u>Numéro du projet</u> <u>Titre du projet</u>	<u>Durée</u> (mois)	<u>Montant</u> (CHF)
Alimonti Andrea , Prof. Dr med. Istituto oncologico della Svizzera italiana (IOSI), Istituto Oncologico di Ricerca (IOR) 6500 Bellinzona	KFS-5262-02-2021 Reverting prostate cancer immunosuppression by hijacking cellular senescence	36	257 700.–
Bachmann Martin , Prof. Dr. Department for BioMedical Research (DBMR), University of Bern 3010 Bern	KFS-5246-02-2021 Intratumour immunotherapy using TLR7/8 loaded nanoparticles formulated with an inflammasome activating micron-sized particulate adjuvant (MCT) in solid murine tumour models	36	371 350.–
Boland Andreas , Prof. Molecular Biology University of Geneva 1211 Geneva	KFS-5453-08-2021 Deciphering the molecular mechanisms underlying chromosome segregation	36	363 050.–
Cejka Petr , Dr. Institute for Research in Biomedicine (IRB) 6500 Bellinzona	KFS-5397-08-2021 Understanding the basis of WRN dependency in microsatellite unstable tumours	36	360 350.–
Chijioke Obinna , Dr. Institute of Experimental Immunology University of Zurich 8057 Zurich	KFS-5292-02-2021 Novel autologous humanized tumour models and their use in target discovery for engineering cellular immunotherapy	36	372 000.–
Coppari Roberto , Prof. Cell Physiology and Metabolism University of Geneva 1211 Geneva	KFS-5253-02-2021 To determine the role of FKBP10 in colorectal cancer	36	375 000.–

Hall Michael N. , Prof. Dr. Biochemistry University of Basel 4056 Basel	KFS-5281-02-2021 Selective mTORC1 inhibition as an innovative anti-cancer approach	18	187 500.–
Held Werner , Prof. Department of Oncology University of Lausanne 1066 Epalinges	KFS-5386-08-2021 Stem cell-like T-cells in tumour immunity and immunotherapy	36	361 750.–
Jacob Francis , Dr. Department of Biomedicine University Hospital Basel 4031 Basel	KFS-5389-08-2021 Innovative ovarian cancer zPDX models for prediction of treatment regimen outcomes in precision medicine	36	346 700.–
Joyce Johanna , Prof. Department of Oncology University of Lausanne 1011 Lausanne	KFS-5280-02-2021 Microenvironmental regulation of therapeutic resistance in glioblastoma	36	361 750.–
Moor Andreas , Prof. Dr. Department of Biosystems Science and Engineering ETH Zurich 4058 Basel	KFS-5444-08-2021 In vivo CRISPR screen in metastasis- accepting organ to identify seeding- promoting and seeding-suppressing interactions	36	323 900.–
Naef Felix , Dr Institute of Bioengineering Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS-5412-08-2021 Translation landscape of eIF5A in hepatocellular carcinoma	48	326 950.–
Pascolo Steve, PD Dr. Klinik für Dermatologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS-5271-02-2021 Enhancing therapy of cancer using immuno- chemotherapeutic RNA nanoparticles and immune check-point inhibition	36	245 450.–
Plückthun Andreas , Prof. Dr. Biochemisches Institut Universität Zürich (UZH) 8057 Zürich	KFS-5290-02-2021 Novel approaches of targeting the RAS subfamily of small GTPases in human cancer	36	344 950.–
Radtke Freddy , Prof. Dr. EPFL-SV-ISREC Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS-5373-08-2021 Tracking the colorectal cancer ecosystem throughout tumour progression on the single- cell level	36	372 500.–
Rätsch Gunnar , Prof. Dr. Department of Computer Science ETH Zurich 8092 Zürich	KFS-5463-08-2021 Deep molecular profiling for microbiome marker detection - informing melanoma immunotherapy	36	358 900.–

Razansky Daniel , Prof. Dr. Institute for Biomedical Engineering University of Zurich 8093 Zurich	KFS-5234-02-2021 Optoacoustic monitoring of radiotherapy response dynamics in murine models of pancreatic cancer for physiological treatment adaptation	24	245 750.–
Scharl Michael , Prof. Dr. med. Department of Gastroenterology and Hepatology University Hospital Zurich 8091 Zurich	KFS-5372-08-2021 Harnessing the potential of selected Clostridiales bacteria as therapeutic approach in colorectal cancer	36	369 150.–
Schoonjans Kristina , Prof. Laboratory of Metabolic Signaling Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS-5379-08-2021 Targeting cancer stem cells in hepatocellular carcinoma	48	375 000.–
Sommer Lukas , Prof. Anatomisches Institut Universität Zürich (UZH) 8057 Zürich	KFS-5391-08-2021 TGF- β signalling in melanoma disease progression and targeted therapy response	36	375 000.–
Stockmann Christian , Dr. med. Anatomisches Institut Universität Zürich (UZH) 8051 Zürich	KFS-5402-08-2021 Vaccination-inspired immunotherapy to target desmoplasia and tumour fibrosis in pancreatic ductal adenocarcinoma	36	365 950.–
Surdez Didier , Prof. Faculty of Medicine University of Zurich 8008 Zurich	KFS-5422-08-2021 Identification of synthetic lethal vulnerabilities in STAG2 mutated Ewing sarcoma	36	374 900.–
Thome-Miazza Margot , Prof. Faculté de biologie et de médecine Université de Lausanne (UNIL) 1066 Epalinges	KFS-5411-08-2021 Role of MALT1-dependent cleavage of the tumour suppressor A20 in lymphomagenesis	48	326 950.–
Tugues Sonia , Dr Institute of Experimental Immunology University of Zurich 8057 Zurich	KFS-5240-02-2021 Innate lymphocyte surveillance of liver metastasis	36	365 450.–
vom Berg Johannes , Dr. Institute of Laboratory Animal Science (LTK) University of Zurich 8952 Schlieren	KFS-5306-02-2021 Elucidating mechanism of action of local, compartment locked immunotherapies in a checkpoint resistant murine brain tumour model and patient derived GB explant culture	36	372 750.–
Werner Sabine , Prof. Dr. Biology ETH Zurich 8093 Zurich	KFS-5408-08-2021 Functional characterization of the fibroblast-cancer cell cross-talk in skin cancer and its control by activin A-mDia2 signalling	36	373 100.–

Wymann Matthias Paul , Prof. Dr. Departement Biomedizin (DBM) Universität Basel 4058 Basel	KFS-5442-08-2021 Deconvolution of metabolic pathways and alleviation of adverse effects in PI3K therapy by use of covalent inhibitors	36	325 000.–
---	--	----	-----------

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bourquin Jean-Pierre Prof. Dr. med. Dr. nat. Abteilung Onkologie Kinderspital Zürich 8032 Zürich	KFS-5298-02-2021 Enhancer factor EP300/CREBBP and metabolic dependencies in high-risk acute lymphoblastic leukaemia	36	375 000.–
Carmona Santiago , Dr Department of Oncology Ludwig Center of Cancer Research at the University of Lausanne 1011 Lausanne	KFS-5409-08-2021 Single-cell analytics for precision immuno- oncology	36	361 750.–
De Dosso Sara , Dr Medical Oncology Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona	KFS-5438-08-2021 Preoperative treatment with metronidazole to evaluate the efficacy in reducing Fusobacterium nucleatum tumour colonization in patients with colorectal cancer: a proof-of-concept trial	24	121 750.–
Dibner Charna , Prof. Medicine University of Geneva 1211 Geneva	KFS-5266-02-2021 Circadian clockwork and the lung tumorigenesis in humans: underlying mechanisms and new avenues for diagnostics and treatment	36	374 950.–
Jandus Camilla , Dr med. Department of Pathology and Immunology, PATIM University of Geneva 1211 Geneva	KFS-5250-02-2021 Innate lymphoid cell (ILC)-driven immune modulation in ovarian cancer	36	369 600.–
Krebs Philippe , Prof, Dr. sc. nat. Institute of Pathology University of Bern 3008 Bern	KFS-5443-08-2021 Role of IL-33 for regulation of the bone marrow niche and fibrosis in myeloproliferative neoplasms	42	374 900.–

Kurzeder Christian , Dr. Gynaecology and Gynaecologic Oncology University Hospital Basel 4031 Basel	KFS-5245-02-2021 Is axillary dissection necessary to determine the need for chemotherapy in patients with clinically node-positive breast cancer?	42	343 450.–
Läubli Heinz , Prof. Medical Oncology Department of Biomedicine University Hospital Basel 4031 Basel	KFS-5239-02-2021 Targeting fibroblast activation protein in patients with liver metastasis by redirection of T-cells	36	373 900.–
Michielin Olivier , Prof. Medical Oncology Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS-5261-02-2021 Digital pathology-based prognostic and predictive biomarker discovery for precision immuno-oncology	36	315 250.–
Müller Anne , Prof. Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich	KFS-5228-02-2021 Identifying and overcoming immune evasion strategies of diffuse large B-cell lymphoma	36	375 000.–
Nardelli Haefliger Denise PD Dr phil. II Service d'urologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS-5237-02-2021 Influence of the microbiota on high risk non- muscle invasive bladder cancer and BCG immunotherapy	36	359 450.–
Pauli Chantal , Ass. Prof. Department for Pathology and Molecular Pathology University Hospital Zurich 8006 Zurich	KFS-5270-02-2021 Uncover therapeutic vulnerabilities in cancer of unknown primary (CUP) by using patient- derived tumour organoids (PDTO), in-depth molecular profiling and pharmacotyping	36	339 650.–
Poyet Cédric , PD Dr. med. Klinik für Urologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS-5308-02-2021 Towards individualization of bladder cancer therapy: the role of microbiome in BCG responsiveness prediction	42	241 050.–
Pruschy Martin , Prof. Dr. sc. nat. Departement für Radio-Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS-5301-02-2021 Radioimmunotherapy-treated primary tumours prime secondary tumours to treatment	36	374 650.–
Rossi Davide , Dr Lymphoma & Genomics Research Program Institute of Oncology Research (IOR) 6500 Bellinzona	KFS-5257-02-2021 Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance	36	367 300.–

Rossi Lorenzo , Dr Oncology and Hematology Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona	KFS-5249-02-2021 SIESTA: a pilot study to investigate and evaluate poor sleep quality in cancer patients following hormonal therapeutic approaches: breast cancer survivors receiving endocrine therapy	24	168 400.–
Schmid Jérôme , Prof. Technique en radiologie médicale Haute école de santé - Genève 1206 Genève	KFS-5460-08-2021 SUBREAM: smart and ultrafast breast MR imaging for cancer detection	36	227 750.–
Schwaller Jürg , Prof. Dr. med. Departement Biomedizin DBM Universitäts-Kinderspital beider Basel (UKBB) 4031 Basel	KFS-5267-02-2021 Modelling, mechanisms and targeting of human acute erythroleukaemia	36	371 600.–
von Garnier Christophe , Prof. Dr. med. Medicine Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS-5433-08-2021 An integrative approach to identify biological and clinical biomarkers for the prediction of immune-mediated pulmonary toxicity in lung cancer patients treated with immune checkpoint inhibitors	36	288 050.–

Psychosoziale Forschung / Recherche psychosociale			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Roser Katharina , Dr. Department of Health Sciences and Medicine University of Lucerne 6002 Lucerne	KFS-5384-08-2021 The long shadow of childhood cancer: socio-bureaucratic hardships after childhood cancer from the perspective of parents, survivors, and legal, healthcare, and insurance experts in Switzerland	36	350 850.–

Epidemiologische Forschung / Recherche épidémiologie			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Ansari Marc , Prof. Dr Unité d'onco-hématologie pédiatrique Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS-5229-02-2021 RELIVE - International registry for paediatric patients with a relapsed or refractory hepatoblastoma or hepatocellular carcinoma	36	62 100.–
Bohlius Julia , PD Dr. med. Swiss TPH, Epidemiology and Public Health Swiss Tropical and Public Health Institute 4051 Basel	KFS-5415-08-2021 The South African cervical cancer screening cohort: improving cervical cancer control in women living in South Africa	36	370 800.–
Bonadies Nicolas Prof. Dr. med. Department of Haematology and Central Haematology Laboratory Inselspital Bern 3010 Bern	KFS-5230-02-2021 I-CARE for MDS: impact of guideline adherence on effectiveness and safety of health care provided to MDS patients	48	375 000.–
Iskandar Rowan , Dr Center of Excellence in Decision- Analytic Modeling and Health Economics Research sitem-insel AG 3010 Bern	KFS-5447-08-2021 Comparative effectiveness and cost- effectiveness of cervical cancer prevention policies in Zambia: mathematical model and interactive web-based learning platform	36	186 700.–
Katapodi Maria , Prof. Dr. Clinical Research Faculty of Medicine University of Basel 4055 Basel	KFS-5293-02-2021 The CASCADE II study: use of genetic information to guide cancer surveillance for hereditary breast/ovarian cancer and lynch syndrome in Switzerland	36	375 000.–
Kuehni Claudia E. Prof. Dr. med. Institut für Sozial- und Präventivmedizin (ISPM) Universität Bern 3012 Bern	KFS-5302-02-2021 Pulmonary dysfunction after childhood cancer: assessing early stage disease (Phase 2)	36	369 150.–
Petignat Patrick , Prof. Unité d'oncogynécologie chirurgicale Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS-5312-02-2021 Promoting comprehensive cervical cancer prevention and better women's health in low- and medium resource settings	36	373 800.–

<p>Rapiti Elisabetta, Prof. Geneva Cancer Registry University of Geneva 1211 Genève</p>	<p>KFS-5243-02-2021 Importance of microsatellite instability, BRAFV600E mutation and immunoscore on colorectal cancer prognosis: a population- based cohort in Geneva</p>	<p>18</p>	<p>169 350.–</p>
<p>Rohner Eliane, Dr. Institute of Social and Preventive Medicine (ISPM) University of Bern 3012 Bern</p>	<p>KFS-5441-08-2021 Cervical pre-cancer treatment failure among women living with HIV in Zimbabwe: a cohort study</p>	<p>48</p>	<p>355 150.–</p>
<p>Vokinger Kerstin Noëlle, Prof. Dr. med. et. Dr. iur. Institute of Law University of Zurich 8001 Zurich</p>	<p>KFS-5462-08-2021 Therapeutic value of new and supplemental indication approvals of cancer drugs, pricing and policy implications</p>	<p>16</p>	<p>92 250.–</p>

Stipendien 2021

Bourses 2021

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Angelillo Julien , Dr med. Department of Pathology and Immunology University of Geneva 1211 Geneva	MD-PhD 5375-06-2021 SAMW MD-PhD Stipendium / Decipher the cross-talk between innate lymphoid cells and tumour-associated lymphatic vessels to improve anti-tumour immunity	26	146 692.–
Chriqui Louis-Emmanuel Service de chirurgie thoracique Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	MD-PhD 5377-06-2021 SAMW MD-PhD Stipendium / Vascular and immune impact of photodynamic therapy combined to immune checkpoint inhibition in malignant pleural mesothelioma: insights from an intravital imaging model	36	191 553.–
Geissler Franziska , Dr. med. Department of Gynecology and Obstetrics University Hospital Basel 4031 Basel	BIL KFS-5445-08-2021 Overcoming PARP inhibitor resistance in BRCA mutated and BRCA methylated ovarian cancer Destination: Ovarian Cancer Laboratory of the Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Melbourne, AUS	18	112 000.–
Pratsinis Manolis , Dr. med. Klinik für Urologie Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	BIL KFS-5248-02-2021 ABCB1 in patients with intermediate and high-risk prostate cancer and DNA repair gene defects treated with a neoadjuvant PARP inhibitor (Niraparib) prior to surgery: assessment of a potential biomarker and correlation with the pathologic response rate Destination: Department of Urologic Surgery, University of California Davis, USA	24	143 500.–

<p>Ruiz Florian Département des neurosciences cliniques Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne</p>	<p>BIL KFS-5456-08-2021 (<i>withdrawn</i>) Dissecting the molecular mechanisms driving glioblastoma heterogeneity</p> <p>Destination: James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Charlestown, USA</p>	<p>24</p>	<p>108 000.–</p>
<p>Stäger Ramon, pract. med. Department of Dermatology University Hospital Zurich 8091 Zurich</p>	<p>MD-PhD 5376-06-2021 SAMW MD-PhD Stipendium / Unravelling the cellular and molecular mechanisms of epithelial skin cancer development through multimodal single cell and spatial analysis</p>	<p>34</p>	<p>179 352.–</p>


Programm zur Stärkung der onkologischen Versorgungsforschung (2020/21)

Programme de renforcement de la recherche sur les services de santé en oncologie (2020/21)

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

 ACCENTUS

 Krebs
Cancer
Cancro

Nationale Strategie gegen Krebs
Stratégie nationale contre le cancer
2014–2020

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Clack Lauren , Prof. Dr. phil. Institut für Implementation Science in Health Care Universität Zürich 8006 Zürich	HSR-5224-11-2020 Improving organised colorectal cancer screening programmes in Switzerland: an implementation science study	24	160 950.–
Le Pogam Marie-Annick , Dr Département Epidémiologie et Services de Santé (DESS) Unisanté - Centre Universitaire de Médecine Générale et Santé Publique 1010 Lausanne	HSR-5225-11-2020 TOCCATA - Impact of the COVID-19 crisis on the quality of Cancer care in Switzerland: a controlled time-series analysis using insurance and hospital claims data	24	130 900.–
Ming Chang , Dr., Department of Clinical Research, University of Basel 4055 Basel	HSR-5222-11-2020 Machine learning techniques for personalized breast cancer prognosis – Swiss BCpro	18	69 150.–
Puhan Milo , Prof. Dr. Institut für Epidemiologie, Biostatistik und Prävention Universität Zürich, 8001 Zürich	HSR-5217-11-2020 Preoperative smoking cessation programme in cancer patients undergoing surgery: a randomized controlled trial	48	249 300.–
Rebmann Chigrinova, Ekaterina , Dr med. Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital Bern 3010 Bern	HSR-5223-11-2020 Analysis of late survival effects, toxicity and outcome of the allogeneic hematopoietic stem cell transplantation for Non-Hodgkin lymphoma in Switzerland. Comparison with autologous stem cell transplantation	18	118 050.–

Scheinemann Katrin, Associate Prof. Dr. med. Pädiatrische Onkologie/Hämatologie, Kantonsspital Aarau AG 5001 Aarau	HSR-5219-11-2020 LENTIL - quaLity critEria iN paediaTric oncoLogy	36	245 300.–
--	---	----	-----------

Weitere Themen

Thèmes Supplémentaires

[Beispielhafte wissenschaftliche Vorhaben](#)

[Exemples de projets scientifiques](#)

[Förderprogramm Versorgungsforschung](#)

[Programme de renforcement de la recherche sur les services de santé](#)